OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076) |
|
|
| Recruiting | 3 | 186 | US | olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar) | Genelux Corporation, GOG Foundation | Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma | 08/25 | 10/26 | | |
| Active, not recruiting | 1/2 | 130 | Canada, US | IMNN-001, Carboplatin, Paclitaxel | Imunon | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 12/24 | 11/25 | | |
| Recruiting | 1/2 | 390 | US | ACR-368, prexasertib, Gemcitabine, OncoSignature | Acrivon Therapeutics, GOG Foundation | Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma | 07/26 | 12/27 | | |
STRO-002-GM1, NCT03748186: Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers |
|
|
| Completed | 1 | 136 | Europe, US | STRO-002 | Sutro Biopharma, Inc. | Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 06/24 | 06/24 | | |
